104 related articles for article (PubMed ID: 32870599)
1. Aberrant expression of TTF1, p63, and cytokeratins in a diffuse large B-cell lymphoma.
Chornenkyy Y; Lin X
Diagn Cytopathol; 2021 Feb; 49(2):E75-E79. PubMed ID: 32870599
[TBL] [Abstract][Full Text] [Related]
2. Expression of P63 and its correlation with prognosis in diffuse large B-cell lymphoma: a single center experience.
Hu WM; Jin JT; Wu CY; Lu JB; Zhang LH; Zeng J; Lin SX
Diagn Pathol; 2019 Nov; 14(1):128. PubMed ID: 31711519
[TBL] [Abstract][Full Text] [Related]
3. An immunohistochemical study of cervical neuroendocrine carcinomas: Neoplasms that are commonly TTF1 positive and which may express CK20 and P63.
McCluggage WG; Kennedy K; Busam KJ
Am J Surg Pathol; 2010 Apr; 34(4):525-32. PubMed ID: 20182342
[TBL] [Abstract][Full Text] [Related]
4. Expression of p63 in diffuse large B-cell lymphoma.
Hedvat CV; Teruya-Feldstein J; Puig P; Capodieci P; Dudas M; Pica N; Qin J; Cordon-Cardo C; Di Como CJ
Appl Immunohistochem Mol Morphol; 2005 Sep; 13(3):237-42. PubMed ID: 16082248
[TBL] [Abstract][Full Text] [Related]
5. The utility of TTF-1, napsin A, CK5 and p63 staining in the sub-classification of non-small cell carcinoma of the lung.
van Zyl A; Schubert PT; Koegelenberg CFN
Cytopathology; 2019 Nov; 30(6):586-591. PubMed ID: 31206846
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D1-positive diffuse large B-cell lymphoma with IGH-CCND1 translocation and BCL6 rearrangement: a report of two cases.
Al-Kawaaz M; Mathew S; Liu Y; Gomez ML; Chaviano F; Knowles DM; Orazi A; Tam W
Am J Clin Pathol; 2015 Feb; 143(2):288-99. PubMed ID: 25596256
[TBL] [Abstract][Full Text] [Related]
7. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells.
Zhou M; Shah R; Shen R; Rubin MA
Am J Surg Pathol; 2003 Mar; 27(3):365-71. PubMed ID: 12604893
[TBL] [Abstract][Full Text] [Related]
8. The role of the cytopathologist in subtyping and epidermal growth factor receptor testing in non-small cell lung cancer: An institutional experience.
Sekar A; Gupta N; Rajwanshi A; Chaturvedi R; Singh N; Lal A
Cytopathology; 2017 Oct; 28(5):371-377. PubMed ID: 28730709
[TBL] [Abstract][Full Text] [Related]
9. Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers.
Wu M; Szporn AH; Zhang D; Wasserman P; Gan L; Miller L; Burstein DE
Diagn Cytopathol; 2005 Oct; 33(4):223-7. PubMed ID: 16138374
[TBL] [Abstract][Full Text] [Related]
10. [Utility of NUT gene expression and rearrangement in diagnosis of NUT midline carcinoma in upper respiratory tract].
Fang W; French CA; Cameron MJ; Han YD; Liu HG
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):519-24. PubMed ID: 23157742
[TBL] [Abstract][Full Text] [Related]
11. p63 protein expression in high risk diffuse large B-cell lymphoma.
Hallack Neto AE; Siqueira SA; Dulley FL; Ruiz MA; Chamone DA; Pereira J
J Clin Pathol; 2009 Jan; 62(1):77-9. PubMed ID: 19103865
[TBL] [Abstract][Full Text] [Related]
12. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.
Hori Y; Yamamoto H; Nozaki Y; Torisu T; Fujiwara M; Taguchi K; Nishiyama K; Nakamura S; Kitazono T; Oda Y
Hum Pathol; 2020 Feb; 96():67-78. PubMed ID: 31734190
[TBL] [Abstract][Full Text] [Related]
13. Aberrant TTF-1 Expression in Peripheral T-Cell Lymphomas: A Diagnostic Pitfall.
Chang ST; Chen SW; Chen BJ; Pan ST; Karube K; Chuang SS
Int J Surg Pathol; 2021 Apr; 29(2):165-168. PubMed ID: 32772757
[TBL] [Abstract][Full Text] [Related]
14. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung.
Wu M; Wang B; Gil J; Sabo E; Miller L; Gan L; Burstein DE
Am J Clin Pathol; 2003 May; 119(5):696-702. PubMed ID: 12760288
[TBL] [Abstract][Full Text] [Related]
15. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray.
Reis-Filho JS; Simpson PT; Martins A; Preto A; Gärtner F; Schmitt FC
Virchows Arch; 2003 Aug; 443(2):122-32. PubMed ID: 12884041
[TBL] [Abstract][Full Text] [Related]
16. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens.
Chhieng DC; Cangiarella JF; Zakowski MF; Goswami S; Cohen JM; Yee HT
Cancer; 2001 Oct; 93(5):330-6. PubMed ID: 11668468
[TBL] [Abstract][Full Text] [Related]
17. Cytokeratin and CD56 aberrant co-expression in diffuse large B-cell lymphoma, NOS misinterpreted as metastatic neuroendocrine carcinoma by FNAC.
Prevodnik VK; Gašljević G
Cytopathology; 2023 Mar; 34(2):165-168. PubMed ID: 36336889
[TBL] [Abstract][Full Text] [Related]
18. p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.
Xu-Monette ZY; Zhang S; Li X; Manyam GC; Wang XX; Xia Y; Visco C; Tzankov A; Zhang L; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Young KH
Aging (Albany NY); 2016 Feb; 8(2):345-65. PubMed ID: 26878872
[TBL] [Abstract][Full Text] [Related]
19. The Value of Cytokeratin 5/6, p63 and Thyroid Transcription Factor-1 in Adenocarcinoma, Squamous Cell Carcinoma and Non-Small-Cell Lung Cancer of the Lung.
Argon A; Nart D; Veral A
Turk Patoloji Derg; 2015; 31(2):81-8. PubMed ID: 25944390
[TBL] [Abstract][Full Text] [Related]
20. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
Wang C; Li W; Liu C; He H; Bai O
Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
